Patients with treatment resistant late-life depression are more likely to respond to antidepressants when sleep is sufficient or has improved.

This variable use of official and unofficial psychiatric diagnoses for political reasons leaves us with a conundrum…

How can psychiatry avoid foolishness and be more like Shakespeare's fools?

SPG302, a regenerative treatment for schizophrenia, could reset the clock on the brain.

Celebrate Psychiatric Times’ 40th anniversary with a look back at some of our previous covers.

John Kane, MD, believes the removal of the REMS requirement for clozapine could help improve utilization for this "grossly underutilized" drug.

Treatments that target negative and cognitive symptoms of schizophrenia could put patients in better control of their life.

Vanda Pharmaceuticals has submitted an NDA for approval of Bysanti for the treatment of acute bipolar I disorder and schizophrenia.

John Kane, MD, shares why you should be paying attention to LB-102 for the treatment of schizophrenia.

Here’s how we can best stand up to hatred…

Do you want to be featured in a future Special Report? Check out our April theme!

A schizophrenia research expert weighs in on the recent announcement concerning SPG302 for the treatment of individuals with schizophrenia.

What percentage of 2025 psychiatric pipeline news was positive vs negative? What disease states are most prominently featured in recent research? Learn more in this exclusive article.

LB Pharmaceuticals presented additional positive data from NOVA1 exploring LB-102 in patients with acutely exacerbated schizophrenia, at the 2025 Annual Congress of the Schizophrenia International Research Society.

Spinogenix announced open enrollment for the phase 2 trial of SPG302, the first synaptic regenerative approach to treat schizophrenia with the potential to improve outcomes across all symptom domains.

Yesterday marked a somber National Doctors’ Day…

In this exclusive interview with Psychiatric Times, John Kane, MD, shares more on the new positive data on LB-102 for the treatment of acutely exacerbated schizophrenia.

In honor of World Bipolar Day, our Mood Disorders Section Editor shares his favorite clinical pearls for treating bipolar disorder.

Here are highlights from this week in Psychiatric Times, including positive clinical trial news for an ADHD treatment and an exclusive interview on the joint statement defending psychotropic medication safety.

In this CME article, learn more about the common neuropsychiatric sequelae of post-acute sequelae of COVID-19, the underlying neurobiological mechanisms, and evidence-based treatments and interventions.

The LGBTQIA+ community has faced marginalization and stereotyping in media, including video games. Let’s examine the intersection of identity, mental health, and video gaming.

"Was this what Rome felt like toward the end? When the colosseums filled with gladiators stirred the masses into a frenzy."

Get ready for our new video series, "Psyched Perspectives"!

A social psychiatrist who stays on the ethical way.

The prevalence of tobacco use in schizophrenia is over 60%—3 times that of the general population. However, the reason for the high prevalence of tobacco use in schizophrenia remains largely unknown.